We will be closed from 5pm BST on Friday 23rd May for the May bank holiday, re-opening at 8.30am BST on Tuesday 26th May. Any orders placed during this period will be processed when we re-open.
The eBooks we sell are sold as a single-user licence and are intended for the end user only.
The sale of some eBooks are restricted to certain countries. To alert you to such restrictions, please select the country of the billing address of your credit or debit card you wish to use for payment.
For further information see https://www.wildy.com/ebook-formats
Once the order is confirmed an e-mail will be sent to you to allow you to download the eBook. For UK purchases this will be automatic. For purchases outside the UK a member of staff will need to confirm the sale. (Staff are available to do this during normal business hours, Mon-Fri 8:30-17:00 UK time)
All eBooks are supplied firm sale and cannot be returned. If you believe there is a fault with your eBook then contact us on ebooks@wildy.com and we will help in resolving the issue. This does not affect your statutory rights.
This new title provides a holistic picture of global cannabis laws and emerging legislative trends for businesses that require a deeper understanding of one of the fastest-moving emerging sectors today.
Individual jurisdictions breaking from international guidance on cannabis legality have opened a Pandora's Box of divergent regulatory regimes across some of the world’s biggest economies. Recent court cases, rulings and directives, along with government initiatives, trials and in some cases total decriminalisation, have created a patchwork of global markets for participants to navigate and serve. These range from fully legal adult recreational markets to nascent medicinal and biopharmaceutical opportunities.
Domestic cannabis initiatives have generated significant opportunities for a range of industries including cosmetics, food and beverage, pharmaceutical, technology and tobacco, despite the exacerbated risks of trading while the UN’s indecision over the drug’s potential rescheduling is ongoing. The cannabis industry itself is at a crossroads due to the legal arbitrage occurring from the varying speeds of maturation. Where Canadian firms have endured more than a decade of IP and trademark litigation issues, for example, many European businesses are only now discovering the roadblocks to patenting products that are by definition illegal under international law.
M&A activity between producers and suppliers is also soaring, causing problems for banking and capital markets firms who may be exposed to federally illegal activity. Overseas investors must also consider proceeds of crime laws that may apply should they be transacting in an activity that is illegal in their home country.
